The CFit Study

Details

Therapeutic category
Other
Trial status
Completed Participating Centres
Phase
Study

Full title

A CFit Study: To what extent does inflammation, oxidative stress, nitric oxide bioavailability and microvascular endothelial dysfunction influence the aerobic exercise function of individuals with cystic fibrosis, with and without established diabetes (The CFit Study)

A CFit Study: To what extent does inflammation, oxidative stress, nitric oxide bioavailability and microvascular endothelial dysfunction influence the aerobic exercise function of individuals with cystic fibrosis, with and without established diabetes (The CFit Study)
Trial Reference Number
99544
Trial type
Non-medication
Intervention
No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit
Recruitment target
0
Last edited date
08/04/2020
CF sponsor
University of Portsmouth
CF sponsor type
Academic

Who can take part?

Top inclusion criteria
  • Established CFRD in accordance with the most recent American Diabetes Association positional statement. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:2 hour OGTT plasma glucose ≥ 200 mg.dL-1.Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1).Glycated hemoglobin ≥ 48 mmol/mol
Top exclusion criteria
  • Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).
  • Unstable co-morbid asthma (daily pulmonary function variability of >20%).

Your donation will make a difference:

Select amount